GCAN Greater Cannabis Company Inc (PK)

GammaCan International, Inc. ("GammaCan" or "the Company") (OTCBB:GCAN), a developer of immunotherapies for the treatment of cancer, today announced that Patrick Schnegelsberg, Chief Executive Officer, is scheduled to present VitiGam�, GammaCan's lead product under development for the treatment of Stage III and Stage IV melanoma, at the 2007 ILSI BioMed 2007 Conference. The Conference will be held from June 5th through June 7th at the David Intercontinental Hotel, in Tel Aviv, Israel. GammaCan�s presentation is scheduled during the Cancer Session, which will take place on Wednesday, June 6th, 2007. About GammaCan GammaCan develops innovative immunotherapy and related approaches to treat cancer. GammaCan's platform technology is based on the use of IgGs, a safe, relatively non-toxic human plasma-derived product used to treat a variety of immune deficiencies and autoimmune diseases. In cancer, IgG-based therapies work by strengthening the patient's immune system. Many experts currently view immunotherapy as a future alternative to chemotherapy. For more information about GammaCan, visit www.GammaCan.com. About VitiGam� VitiGam� is a first-in-class IgG-based anti-cancer immunotherapy being developed for the treatment of Stage III and Stage IV melanoma. GammaCan is planning to submit its Investigational New Drug Application (IND) for VitiGam� to the FDA in the near future. The Company expects to commence human clinical trials shortly thereafter. VitiGam� is an IgG-based product manufactured from the plasma of donors with Vitiligo, a benign skin condition affecting up to 2% of the general population. Studies have shown that this "enriched" IgG formulation contains potent anti-melanoma activity. Based on these studies, GammaCan expects VitiGam� to provide both, specific anti-melanoma activity (directed against melanoma cells), and non-specific anti-cancer activity. About Melanoma Melanoma is a deadly form of skin cancer. According to the American Cancer Society, melanoma accounts for approximately 4% of all skin cancers but causes about 75% of all skin cancer-related deaths. An estimated 62,000 people will be diagnosed with and nearly 8,000 people will die from melanoma in the U.S. alone in 2007. If rapidly diagnosed and surgically removed, early-stage melanoma is usually curable. However, for patients with metastatic melanoma (including Stage II and Stage IV), the prognosis is poor resulting from limited treatment alternatives, a median survival time of 8.5 months, and a 5-year survival rate of 3%. There has been little change in these results for in excess of 25 years. The incidence of melanoma has increased more rapidly than any other cancer during the past 10 years. The last drug to treat patients with metastatic melanoma was approved by the FDA over 30 years ago. Safe Harbor Statement: Statements in this document that are not purely historical are forward-looking statements. Forward-looking statements in this release include statements regarding: the commercialization of anti-cancer immunotherapies and the Company's efforts to develop therapies to boost the immune systems of cancer patients by the use of IgG-based therapy. Actual outcomes and the Company's actual results could differ materially from those in such forward-looking statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the inability to finance the planned development of the technology, the inability to hire appropriate staff to develop the technology, unforeseen technical difficulties in developing the technology, the inability to obtain regulatory approval for human use, competitors' therapies proving to be more effective, cheaper or otherwise preferable for consumers, the inability to market a product, all of which could, among other things, delay or prevent product release, as well as other factors expressed from time to time in GammaCan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with GammaCan's periodic filings with the SEC, which are incorporated herein by reference. The forward-looking statements contained herein are made only as of the date of this press release, and GammaCan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.